NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

Purpose/Objective(s)Recurrent T1 bladder cancer has a substantial rate of progression and is usually treated with radical cystectomy. Bladder preservation therapy is a well-established approach for the treatment of muscle invasive urothelial cancer of the bladder. RTOG 0926 was a single arm, phase II trial investigating the use of trimodality bladder preservation therapy for recurrent, high-grade non-muscle invasive urothelial...